Wells Fargo Lowers FY12 Estimates on MannKind (MNKD); Cash Burn Slowed, But Critical Data Not Out Til '13

July 9, 2012 1:31 PM EDT
Get Alerts MNKD Hot Sheet
Price: $0.69 +7.81%

Rating Summary:
    5 Buy, 4 Hold, 6 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 24 | Down: 17 | New: 14
Trade MNKD Now!
Join SI Premium – FREE
Wells Fargo maintains a 'Market Perform' on MannKind (NASDAQ: MNKD) price target range $2-$3.

Analyst, Michael Tong, said, "Sale of 31.25MM shares to The Mann Group in exchange for debt cancellation ($77.2MM), while dilutive, should help to modestly reduce MNKD's near-term cash burn. Slightly widening 2012E loss per share to $0.97 (from loss of $0.95) on slightly lower share count, as we previously estimated mid-Q2 closing of this share sale."

"We believe in the commercial viability of Afrezza, especially if its close mimic to the natural insulin response can be replicated in actual everyday clinical usage. However, with data readout from the MKC-171/175 studies not due to occur until early 2013, we find meaningful near-term share price appreciation unlikely."

For an analyst ratings summary and ratings history on MannKind click here. For more ratings news on MannKind click here.

Shares of MannKind closed at $2.75 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View

Related Entities

Wells Fargo


Wells Fargo "shorting" MNKD
Robin on 2012-08-21 13:37:38
Mark as Spam | Reply to this comment

This is obvious to anyone that has seen stock manipulation for years now with MNKD. They are praying Al doesn't get a partner or some creative financing deal done - that would screw Wells Fargo in the arse.

Add Your Comment